Your session is about to expire
← Back to Search
Peresolimab for Rheumatoid Arthritis (RESOLUTION-1 Trial)
RESOLUTION-1 Trial Summary
This trial will test a new drug, peresolimab, to treat adults with moderate to severe rheumatoid arthritis. The goal is to see if it is safe and effective.
RESOLUTION-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RESOLUTION-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have active RA with 6 or more swollen and tender joints.My rheumatoid arthritis is severe, limiting my ability to move.I have not responded well to at least one standard arthritis treatment.I have been diagnosed with rheumatoid arthritis for at least 3 months.I have been diagnosed with rheumatoid arthritis for at least 3 months.I have moderate to severe active rheumatoid arthritis.I have a chronic inflammatory or connective tissue disease other than rheumatoid arthritis.I have 6 or more swollen joints.I have not responded well to at least one standard arthritis treatment.
- Group 1: Peresolimab Dose 1
- Group 2: Peresolimab Dose 2
- Group 3: Placebo
- Group 4: Peresolimab Dose 3
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current participant capacity of this experiment?
"Correct. The trial manifest on clinicaltrials.gov attests to the fact that this medical experiment, which was first posted in August of 2022, is presently enrolling patients. Approximately 420 participants must be enlisted from a total of 54 various sites."
Is it still possible to register for this clinical trial?
"The evidence on clinicaltrials.gov suggests that this research project is actively seeking participants, after being initiated at the end of August 2022 and last modified in early November 2022."
To what degree have hospitals adopted this research protocol?
"In this clinical trial, 54 diverse medical centres are enrolling patients. These include Arthritis Northwest, PLLC in Spokane and Dynamed Clinical Research, LP d/b/a DM Clinical Research in Tomball as well as the Piedmont Arthritis Clinic of Greenville alongside numerous other locations."
Could you explain the potential hazards of Peresolimab usage?
"While Peresolimab has not yet been proven effective, there is prior data that suggests it may be safe. Therefore, our team at Power rated its safety a 2 on a 3-point scale."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger